Sensitivity analyses of the 5-y EFS with second-line CART in primary refractory/early relapse patients compared with SOC
| 5-y EFS with second-line CAR-T . | Cost-effectiveness . | Proportion of simulations that second-line CAR-T is cost-effective at various WTP thresholds . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Life-years gained . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 USD) . | Incremental cost . | ICER . | $50 000 . | $100 000 . | $150 000 . | |
| 20% | 1.02 | 3.99 | 1.39 | $832 497 | $324 463 | $233 967 | 4% | 19% | 31% |
| 25% | 2.12 | 4.47 | 1.87 | $812 288 | $304 254 | $162 778 | 7% | 26% | 47% |
| 30% | 2.65 | 4.95 | 2.35 | $792 068 | $284 033 | $121 024 | 15% | 44% | 61% |
| 35% | 3.29 | 5.42 | 2.82 | $771 838 | $263 804 | $93 547 | 34% | 57% | 73% |
| 40% | 3.88 | 5.90 | 3.29 | $751 602 | $243 568 | $73 968 | 41% | 72% | 84% |
| 5-y EFS with second-line CAR-T . | Cost-effectiveness . | Proportion of simulations that second-line CAR-T is cost-effective at various WTP thresholds . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Life-years gained . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 USD) . | Incremental cost . | ICER . | $50 000 . | $100 000 . | $150 000 . | |
| 20% | 1.02 | 3.99 | 1.39 | $832 497 | $324 463 | $233 967 | 4% | 19% | 31% |
| 25% | 2.12 | 4.47 | 1.87 | $812 288 | $304 254 | $162 778 | 7% | 26% | 47% |
| 30% | 2.65 | 4.95 | 2.35 | $792 068 | $284 033 | $121 024 | 15% | 44% | 61% |
| 35% | 3.29 | 5.42 | 2.82 | $771 838 | $263 804 | $93 547 | 34% | 57% | 73% |
| 40% | 3.88 | 5.90 | 3.29 | $751 602 | $243 568 | $73 968 | 41% | 72% | 84% |
In this table, the 5-year EFS is varied from 20% to 40%, and the clinical outcomes (OS), effectiveness (life-years gained and QALY), and total cost related to RR-DLBCL are displayed. USD, US dollars.